Post-Conference Perspectives: Recent Advances in the Management of Chronic GvHD - Episode 5

Understanding Mechanisms of Action: Ruxolitinib, Ibrutinib, and Belumosudil

,

Dr. Merin describes the mechanisms of action of ruxolitinib, ibrutinib, and belumosudil and shares clinical pearls for community oncologists on methods for achieving response with these agents.

EP. 1: The Chronic GvHD Landscape: Risk Factors and Diagnosis
EP. 2: First-line Treatment for Patients with Chronic GvHD
EP. 3: Defining and Managing Steroid Refractory Chronic GvHD
EP. 4: Role of Ruxolitinib in Steroid-Refractory Chronic GvHD
Now Viewing
EP. 5: Understanding Mechanisms of Action: Ruxolitinib, Ibrutinib, and Belumosudil
EP. 6: Key Efficacy Data of Ibrutinib and Belumosudil in Steroid-Refractory Chronic GvHD Patients
EP. 7: Real World Data on the Use of Ruxolitinib and Treatment Selection in chronic GvHD
EP. 8: Future Directions in Chronic GvHD